Skip to main navigation
For additional product information, please see

Product Information

  • AviseTest.com

Contact Us

  • Contact Us

Social

Exagen Diagnostics - Logo
  • About Exagen
    • Exagen Quality
    • Lab Certifications
  • Our Products
    • AVISE CTD
      • SLE & Connective Tissue Disease Test
    • AVISE Lupus
      • SLE Diagnostic Test
    • AVISE SLE Monitor
      • SLE Disease Monitoring Test
    • AVISE SLE Prognostic
      • SLE Prognostic Test
    • AVISE APS
      • Antiphospholipid Syndrome Test
    • AVISE MTX
      • Methotrexate Polyglutamate Measuring Test
    • AVISE HCQ
      • The Hydroxychloroquine (HCQ) test measuring drug levels in whole blood
    • AVISE Anti-CarP
      • RA Diagnosis & Prognosis
  • Our People
    • Leadership
    • Board of Directors
    • Careers
  • Our Science
    • CB-CAPs – Lupus Biomarkers
    • Clinical Trials
    • Research & Development
    • Publications
  • Business Development
    • Business Development
    • Partners
  • ESG
    • Corporate Governance
    • ESG Report
  • Investors

    Investor Relations

    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Annual Report
    • SEC Filings
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Investor Contacts
    • Email Alerts
Image

SEC Filing Details

SEC Filing Details

Document Details

Form
144
Filing Date
Oct 8, 2024
Document Date
Oct 8, 2024
Form Description
Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Filing Group
Other
Company
Exagen
Issuer
EXAGEN INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
Print Page
Email Alerts
RSS Feeds
Investor Contacts
© 2024 Exagen Inc. | All Rights Reserved

Footer

  • Terms of Use
  • Notice of Privacy Practices
  • Lab Certifications
  • Contact Us

Social

Image

© 2024 Exagen Inc. | All Rights Reserved

Footer

  • Terms of Use
  • Notice of Privacy Practices
  • Lab Certifications
  • Contact Us

Social

Exagen Quality Seal
  • About Exagen
    • ← Back
    • Exagen Quality
    • Lab Certifications
  • Our Products
    • ← Back
    • AVISE CTD
      • ← Back
      • SLE & Connective Tissue Disease Test
    • AVISE Lupus
      • ← Back
      • SLE Diagnostic Test
    • AVISE SLE Monitor
      • ← Back
      • SLE Disease Monitoring Test
    • AVISE SLE Prognostic
      • ← Back
      • SLE Prognostic Test
    • AVISE APS
      • ← Back
      • Antiphospholipid Syndrome Test
    • AVISE MTX
      • ← Back
      • Methotrexate Polyglutamate Measuring Test
    • AVISE HCQ
      • ← Back
      • The Hydroxychloroquine (HCQ) test measuring drug levels in whole blood
    • AVISE Anti-CarP
      • ← Back
      • RA Diagnosis & Prognosis
    • AVISE PC4d
      • ← Back
      • History of SLE Thrombosis
  • Our People
    • ← Back
    • Leadership
    • Board of Directors
    • Careers
  • Our Science
    • ← Back
    • CB-CAPs – Lupus Biomarkers
    • Clinical Trials
    • Research & Development
    • Publications
  • Business Development
    • ← Back
    • Business Development
    • Partners
  • ESG
    • ← Back
    • Corporate Governance
    • ESG Report
  • Investors

    Investor Relations

    • ← Back
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Annual Report
    • SEC Filings
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Investor Contacts
    • Email Alerts